7-Hydroxy Kratom Vapes Explained: Ingredients, Formats, and Research

Author : william Gibson | Published On : 27 Aug 2026

7-Hydroxy Kratom Vapes Explained: Ingredients, Formats, and Research

7-hydroxymitragynine, commonly called 7-OH, is one of the most closely studied alkaloids associated with Mitragyna speciosa, the plant commonly known as kratom. Although 7-OH occurs naturally in kratom leaves, it is normally present only in relatively small quantities. Modern commercial products have increasingly included concentrated 7-OH, including tablets, gummies, liquid products, and vaping formulations.

This development has attracted scientific and regulatory attention because concentrated 7-OH products are pharmacologically different from traditional kratom leaf preparations. Research has identified significant activity at opioid receptors, while questions remain about the safety, composition, pharmacokinetics, and long-term effects of newer product formats such as vapes.  

What Is 7-Hydroxymitragynine?

7-hydroxymitragynine is an alkaloid associated with Mitragyna speciosa. Kratom contains dozens of naturally occurring alkaloids, with mitragynine generally being the most abundant. 7-OH is present naturally but at much lower concentrations.

According to an FDA scientific assessment, 7-OH typically occurs in botanical kratom at approximately 0.1–0.4% of dry weight. This distinction is important because concentrated commercial products can contain considerably more 7-OH than would normally be encountered in unprocessed kratom leaf. ( 

Scientific research has focused heavily on how 7-OH interacts with the mu-opioid receptor (MOR). Laboratory and animal studies indicate that it has substantially stronger opioid-receptor activity than mitragynine. Researchers have also investigated its relationship with analgesia, tolerance, dependence, withdrawal, and respiratory effects.  

What Are 7-OH Kratom Vapes?

7-OH kratom vapes are vaping products marketed as containing 7-hydroxymitragynine or kratom-derived alkaloids. Unlike conventional kratom powders, teas, capsules, or extracts that are generally swallowed, vaping formulations are designed to deliver their ingredients through inhalation.

The distinction matters because inhaled substances can follow a very different absorption pathway from orally consumed substances. The lungs can introduce chemicals directly into systemic circulation, potentially changing how quickly and extensively compounds reach the bloodstream.

However, there is an important limitation in the current evidence: there is very little clinical research establishing the safety, pharmacokinetics, or long-term consequences of inhaling 7-OH-containing formulations.

A recent analysis of nonswallowed kratom-derived products identified vaping products as the largest category among the products examined. Researchers also found that many contained 7-OH and that some contained additional intoxicating cannabinoids. The study emphasized the absence of adequate clinical, safety, and pharmacokinetic data for these products. ( 

Common Ingredients and Formulation Components

The exact composition of a 7-OH vape can vary substantially between products. A product marketed as a “7-OH vape” may not contain only 7-hydroxymitragynine.

Potential formulation categories can include:

• 7-hydroxymitragynine or a concentrated kratom-derived extract

• Other kratom alkaloids, including mitragynine

• Carrier ingredients used in vaping formulations

• Flavoring compounds

• Sweeteners or other formulation additives

• Cannabinoids or other psychoactive substances in some products

The presence and concentration of these ingredients cannot reliably be determined from product names alone.

This is one reason laboratory testing is particularly important when evaluating novel botanical products. A label may identify a principal ingredient without providing a complete picture of the formulation or its contaminants.

Researchers studying commercially available kratom products have reported substantial differences in alkaloid concentrations. Quality-control problems can therefore create uncertainty about the actual chemical composition of individual products.  

How Do Vape Products Differ From Traditional Kratom?

Traditional kratom is commonly encountered as dried leaf powder, tea, capsules, or extracts. These preparations are generally administered orally.

Vaping represents a fundamentally different delivery format.

With oral products, compounds pass through the gastrointestinal system and may undergo metabolism before reaching systemic circulation. Inhaled products can bypass much of this first-pass process.

That difference is scientifically significant because absorption rate, bioavailability, metabolism, and peak blood concentrations can all influence pharmacological effects.

Unfortunately, researchers do not yet have enough high-quality human data to establish how vaping 7-OH compares pharmacokinetically with oral kratom or concentrated 7-OH products. The absence of data should not be interpreted as evidence that vaping is safer or more predictable.

What Does the Research Say About 7-OH?

Research into 7-OH has expanded considerably during the past several years.

A 2025 review examined approximately 150 papers concerning mitragynine and 7-hydroxymitragynine, covering chemistry, pharmacology, toxicity, and future research directions. The authors noted that considerable scientific work has focused on these two alkaloids while important research gaps remain. 

7-OH has demonstrated significant activity at the mu-opioid receptor in laboratory research. Earlier pharmacological reviews describe it as a substantially more potent opioid-receptor agonist than mitragynine. Animal research has also identified effects associated with opioid activity, including respiratory depression at sufficiently high exposures and behaviors associated with tolerance and dependence.  

These findings are important because they challenge the idea that concentrated 7-OH products can simply be treated as equivalent to ordinary botanical kratom.

At the same time, researchers continue to distinguish between naturally occurring kratom leaf and products containing enhanced or concentrated levels of 7-OH.

Why Vaping Creates Additional Research Questions

Vaping introduces several variables that are not present in traditional oral kratom research.

First, researchers need to understand how effectively 7-OH and other constituents are absorbed through the lungs. Second, they need to determine whether heating changes the chemical composition of the formulation.

Thermal degradation is an important consideration for any inhaled chemical mixture. A compound that is relatively stable in its original formulation may behave differently when exposed to high temperatures.

There are also questions about the vaping hardware itself. Heating coils, cartridges, solvents, flavoring agents, and manufacturing materials may all affect what ultimately enters the respiratory system.

At present, there is insufficient evidence to establish a reliable safety profile for inhaled 7-OH products.

Safety and Potential Risks

The safety concerns surrounding concentrated 7-OH have become increasingly prominent.

The FDA states that products containing concentrated 7-OH have not been demonstrated to be safe or effective for medical use and warns consumers about potential serious harms. Reported concerns include addiction, withdrawal symptoms, gastrointestinal problems, insomnia, seizures, anxiety, and depression.  

The FDA has also emphasized the distinction between trace naturally occurring 7-OH in kratom leaf and products containing concentrated or enhanced levels of the compound. 

For vaping products specifically, there is an additional concern involving the respiratory route of exposure. Current research does not provide enough evidence to determine the long-term pulmonary effects of repeatedly inhaling 7-OH-containing formulations.

Another concern is product consistency. Two products carrying similar names may contain substantially different concentrations or additional psychoactive compounds.

Regulatory Developments

The regulatory environment surrounding 7-OH has been changing rapidly.

In July 2025, the FDA announced actions concerning companies marketing products containing 7-hydroxymitragynine and described concentrated 7-OH products as a growing public-health concern. 

More recently, the FDA reported that on July 1, 2026, the DEA began a temporary scheduling process involving 7-OH above a proposed threshold, along with certain synthetic kratom-related compounds. The agency also opened a public-comment process concerning the proposed threshold. (

Because regulations can differ by jurisdiction and continue to change, consumers, researchers, and businesses should check the applicable laws where they are located rather than relying on older information.

What Should Consumers Look for in Product Information?

From a research and product-quality perspective, transparency is especially important for novel kratom formulations.

Useful information may include:

• Complete ingredient disclosure

• Clearly stated alkaloid identity

• Independent laboratory testing

• Batch-specific analytical results

• Testing for contaminants

• Manufacturing information

• Appropriate warnings and labeling

• Clear information about whether additional psychoactive compounds are present

A Certificate of Analysis can provide useful analytical information, although the existence of a COA alone does not establish that a product is safe.

For inhaled products, additional questions about aerosol composition, thermal stability, and potential contaminants are particularly relevant.

The Future of 7-OH Research

Scientific interest in 7-hydroxymitragynine is likely to continue as researchers investigate its chemistry, receptor activity, metabolism, toxicology, and potential risks.

One of the largest research gaps concerns real-world commercial formulations. Much of the existing scientific literature focuses on isolated compounds, traditional kratom preparations, laboratory models, or animal studies. Commercial vaping products introduce additional variables that are not adequately represented in those studies.

Future research will need to examine human pharmacokinetics, inhalation toxicology, product composition, long-term exposure, interactions with other substances, and differences between naturally occurring kratom alkaloids and concentrated formulations.

Final Thoughts

7-hydroxymitragynine is a pharmacologically active kratom alkaloid that has attracted substantial scientific attention because of its strong interaction with opioid receptors. The emergence of concentrated 7-OH products, including vaping formulations, has created an additional area of research and regulatory concern.

While traditional kratom and concentrated 7-OH products are sometimes discussed together, they should not automatically be considered equivalent. Concentration, formulation, delivery method, and additional ingredients can significantly change the exposure profile.